Aptose Biosciences (NASDAQ: APTO) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15).“Aptose now is clinically ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE